While one study in mice showed that the injection of recombinant IL-6 into mice was not sufficient to induce albuminuria or renal injury [60], a recent clinical study revealed the ameliorating effect of an IL-6 receptor antibody (tocilizumab) in a certain type of nephrotic syndrome, namely, Castleman disease [61]. Here, IL6 is linked to Castleman disease.